CRIS - Curis Inc logo

Curis Inc

CRIS

Curis Inc is a biotechnology company focused on developing drug candidates for cancer treatment. Its pipeline includes drugs for various cancers, with collaborations for commercializing Erivedge and advancements in immuno-oncology and precision oncology.

βš•οΈ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 20 years ago β†’$0today

Score Overview

1 Year
Score
Net Growth-178.99%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-54.32%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score4.4
Net Growth53.44%
Net Trend60%
Net Income Consistencyβ€”
Rev Growth-59.49%
Rev Trend20%
Revenue Consistencyβ€”
10 Years
Score
Net Growth64.98%
Net Trend70%
Net Income Consistency
Rev Growth-42.69%
Rev Trend40%
Revenue Consistency
20 Years
Score2.4
Net Growth-139.58%
Net Trend55%
Net Income Consistency
Rev Growth-71.12%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth93.96%
Net Trend54%
Net Income Consistency
Rev Growth332.66%
Rev Trend46%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Curis Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • CRIS

2011: 66.7% Β· 2021: 96.9% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 0.83β€”
1 Year2025-09-26
$ 33.80-97.54%
5 Years2021-09-28
$ 3.18K-99.97%
10 Years2016-09-28
$ 5K-99.98%
20 Years2006-09-28
$ 2.9K-99.97%
All Time2000-08-01
$ 48.75K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 4M-$ 21M$ 5M
2025$ 9M-$ 7M$ 5M
2024$ 10M-$ 43M$ 19M
2023$ 10M-$ 47M$ 56M
2022$ 10M-$ 60M$ 85M
2021$ 10M-$ 45M$ 115M
2020$ 10M-$ 29M$ 168M
2019$ 10M-$ 32M$ 20M
2018$ 10M-$ 32M$ 24M
2017$ 9M-$ 53M$ 60M
2016$ 7M-$ 60M$ 44M
2015$ 7M-$ 58M$ 82M
2014$ 9M-$ 18M$ 50M
2013$ 15M-$ 12M$ 68M
2012$ 16M-$ 16M$ 58M
2011$ 14M-$ 9M$ 235.91K
2010$ 15M-$ 4M$ 40M
2009$ 8M-$ 9M$ 25M
2008$ 8M-$ 12M$ 28M
2007$ 16M-$ 6M$ 41M
2006$ 14M-$ 8M$ 36M
2005$ 6M-$ 14M$ 44M
2004$ 4M-$ 13M$ 49M
2003$ 11M-$ 11M$ 35M
2002$ 18M-$ 82M$ 40M
2001$ 1M-$ 81M$ 52M
IPO2000$ 997.08K-$ 350M$ 75M
CRIS - Curis Inc logo

Curis Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 10M to $ 9M and net income went from -$ 29M to -$ 7M. Revenue increased in 1 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 7M to $ 9M and net income went from -$ 58M to -$ 7M. Revenue increased in 4 of those 10 years; net income in 7.

Curis Inc currently holds a 20-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.

Membership

Continue CRIS’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies